San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Artiva Biotherapeutics is raising $120,000,001.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Fred Aslan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Artiva Biotherapeutics

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities.

To learn more about Artiva Biotherapeutics, visit http://www.artivabio.com/

Contact:
Fred Aslan, Chief Executive Officer
858-267-4467
https://www.linkedin.com/in/fred-aslan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved